AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BALTIMORE -- A genetic screen for two metabolic enzymes identified women with ovarian cancer who did not respond to treatment with paclitaxel in a preliminary study with 41 patients.
This is the first time that a genetic screen for metabolic enzymes has distinguished patients who respond to cancer chemotherapy drugs from patients who are unable to respond to the drugs, Dr. J. Fernando Arena said at the annual meeting of the American Society of Human Genetics.
If the genetic screen is further refined and validated, it has the potential to identify early on those ovarian cancer patients who won't respond to standard therapy, thereby avoiding a time-consuming course of ineffective treatment, Dr. Arena, said.
The standard, first-line regimen for chemotherapy of epithelial, ovarian cancer is a combination regimen of paclitaxel and carboplatin. About 65% of women respond to the regimen.
Applying the genetic screen to a group of 41 patients identified a group of non-responders, of whom 60% failed to respond to the regimen, and a group of responders, of whom 96% responded, said Dr. Arena, director of translational research at the Familial Ovarian/Breast Cancer Center of the University of Miami.
...
Source: HighBeam Research, Investigational genetic screen may predict chemotherapy responders....